Viva Biotech Holdings (VBIZF)
OTCMKTS
· Delayed Price · Currency is USD
0.2270
-0.0723 (-24.16%)
At close: Apr 14, 2025
Viva Biotech Holdings Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Net Income | 167.29 | -116.11 | -528.48 | 287.55 | -386.88 | Upgrade
|
Depreciation & Amortization | 213.86 | 211.22 | 185.45 | 153.15 | 70.19 | Upgrade
|
Other Amortization | - | - | - | - | 5.07 | Upgrade
|
Loss (Gain) From Sale of Assets | 1.91 | -0.28 | 1.9 | 4.84 | -1.34 | Upgrade
|
Asset Writedown & Restructuring Costs | - | 13.82 | - | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | -78.11 | 19.81 | 373.59 | -53.75 | -110.22 | Upgrade
|
Loss (Gain) on Equity Investments | 0.1 | - | - | - | 0.49 | Upgrade
|
Stock-Based Compensation | 4.19 | 19.01 | 24.82 | 20.58 | 14.05 | Upgrade
|
Other Operating Activities | 97.69 | 204.54 | 346.67 | -73.03 | 514.81 | Upgrade
|
Change in Accounts Receivable | -18.68 | 30.44 | -22.31 | -98.51 | -41.53 | Upgrade
|
Change in Inventory | -17.48 | 57.04 | -96.44 | -69.07 | -1 | Upgrade
|
Change in Accounts Payable | 63.6 | -80.37 | 45.08 | -16.44 | -36.78 | Upgrade
|
Change in Unearned Revenue | 0.39 | -19.72 | -18.7 | -5.74 | -0.17 | Upgrade
|
Change in Other Net Operating Assets | -60.77 | 44.03 | 74.47 | -71.76 | 16.49 | Upgrade
|
Operating Cash Flow | 373.99 | 383.41 | 386.05 | 77.83 | 43.18 | Upgrade
|
Operating Cash Flow Growth | -2.46% | -0.69% | 396.02% | 80.24% | -6.15% | Upgrade
|
Capital Expenditures | -190.67 | -187.68 | -249.33 | -565.18 | -592.62 | Upgrade
|
Sale of Property, Plant & Equipment | 0.55 | 0.65 | 0.66 | 1.58 | 0.13 | Upgrade
|
Cash Acquisitions | - | - | -81.2 | -210.87 | -2,510 | Upgrade
|
Divestitures | 15 | 32.34 | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -1 | -0.16 | -0.21 | -1.15 | -25.24 | Upgrade
|
Investment in Securities | 137.9 | 50.11 | -48.03 | -159.05 | -124.42 | Upgrade
|
Other Investing Activities | 224.12 | 543.91 | 5.31 | 65.84 | -597.43 | Upgrade
|
Investing Cash Flow | 185.9 | 439.17 | -372.8 | -868.84 | -3,849 | Upgrade
|
Long-Term Debt Issued | 1,120 | 2,045 | 673.04 | 565.03 | 4,527 | Upgrade
|
Total Debt Issued | 1,120 | 2,045 | 673.04 | 565.03 | 4,527 | Upgrade
|
Long-Term Debt Repaid | -1,740 | -2,875 | -745.6 | -989.64 | -68.73 | Upgrade
|
Total Debt Repaid | -1,740 | -2,875 | -745.6 | -989.64 | -68.73 | Upgrade
|
Net Debt Issued (Repaid) | -620.51 | -829.54 | -72.56 | -424.61 | 4,458 | Upgrade
|
Issuance of Common Stock | - | - | - | 18.23 | 984.26 | Upgrade
|
Repurchase of Common Stock | -23.02 | -10.27 | - | -146.19 | -66.26 | Upgrade
|
Common Dividends Paid | - | - | - | -16.27 | -51.79 | Upgrade
|
Dividends Paid | - | - | - | -16.27 | -51.79 | Upgrade
|
Other Financing Activities | -14.23 | 410.32 | -70.64 | -84.31 | -17.31 | Upgrade
|
Financing Cash Flow | -657.76 | -429.5 | -143.2 | -653.16 | 5,307 | Upgrade
|
Foreign Exchange Rate Adjustments | 3.26 | -35.32 | 7.57 | -63.34 | -96.91 | Upgrade
|
Net Cash Flow | -94.61 | 357.75 | -122.38 | -1,508 | 1,404 | Upgrade
|
Free Cash Flow | 183.32 | 195.73 | 136.72 | -487.35 | -549.44 | Upgrade
|
Free Cash Flow Growth | -6.34% | 43.16% | - | - | - | Upgrade
|
Free Cash Flow Margin | 9.23% | 9.08% | 5.75% | -23.16% | -78.83% | Upgrade
|
Free Cash Flow Per Share | 0.06 | 0.10 | 0.07 | -0.25 | -0.35 | Upgrade
|
Cash Interest Paid | 53.76 | 70.69 | 72.86 | 71.28 | 11.83 | Upgrade
|
Cash Income Tax Paid | 79.13 | 80.33 | 80.51 | 45.15 | 17.17 | Upgrade
|
Levered Free Cash Flow | 188.26 | 143.45 | 2.66 | -429.06 | -809.22 | Upgrade
|
Unlevered Free Cash Flow | 221.94 | 253.82 | 118.08 | -314.62 | -775.45 | Upgrade
|
Change in Net Working Capital | -52.01 | -91 | 8.88 | 70.09 | 312.16 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.